FNY Investment Advisers’s Vir Biotechnology VIR Stock Holding History

FNY Investment Advisers’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50K	Hold	5,000	–	–	0.02%	416
2026 Q1	$44K	Buy	+5,000	New	+$39.8K	0.02%	381
2025 Q4	–	Sell	-6,825	Closed	-$38K	–	1504
2025 Q3	$38K	Buy	+6,825	New	+$34.9K	0.01%	556

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

FNY Investment Advisers's VIR Position: Q2 2026 in Review

FNY Investment Advisers held its Vir Biotechnology (VIR) position steady in Q2 2026 at 5,000 shares worth $50K. The position accounts for 0.02% of the portfolio, ranked #416.

FNY Investment Advisers first reported a position in VIR in Q3 2025 and has held it in 3 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

FNY Investment Advisers held 5,000 shares of Vir Biotechnology worth $50K as of Q2 2026.
FNY Investment Advisers left its Vir Biotechnology share count unchanged in Q2 2026.
Vir Biotechnology made up 0.02% of FNY Investment Advisers's portfolio in Q2 2026, its #416 holding.
FNY Investment Advisers first reported a position in Vir Biotechnology in Q3 2025 and has held it in 3 quarters since.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.